Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Regional Health - Americas

Topics

Medicine

Internal Medicine

Endocrinology

Endocrinology, Diabetes And Metabolism

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.lana.2024.100814